Lunsumio (Mosunetuzumab-axgb) for Lymphoma

Overview
Lunsumio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory follicular lymphoma who have already tried two types of systemic therapy. Lunsumio may be referred to by its drug name, mosunetuzumab-axgb.

Lunsumio is a bispecific T-cell engager. The drug consists of a genetically engineered protein, or antibody, that targets the CD20 protein on lymphoma B cells and the CD3 protein on T cells. Lunsumio is believed to work by inducing T cells to kill lymphoma B cells.

How do I take it?
Lunsumio is administered as an intravenous (IV) infusion on specific days in scheduled cycles. Lunsumio comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Lunsumio lists common side effects including cytokine release syndrome (CRS), a potentially fatal inflammatory reaction with severe neurological symptoms such as hallucinations and tremors. Other common side effects of Lunsumio are fatigue, rash, fever, and headache.

Other rare but serious side effects listed for Lunsumio can include neurological damage, infections, abnormal blood count, tumor flare (a reaction in which cancer seems to worsen), and fetal harm.

For more details about this treatment, visit:

Lunsumio — Genentech
https://www.lunsumio.com